发布求助
文献互助 智能选刊 最新文献

Seminars in cutaneous medicine and surgery最新文献

筛选
英文 中文
Aesthetic Consideration in Women's Health, Introduction. 妇女健康中的美学考虑》，导言。
Seminars in cutaneous medicine and surgery Pub Date : 2018-12-01 DOI: 10.12788/j.sder.2018.058
Lauren Meshkov Bonati, Mona Sadeghpour, Nicola A Quatrano
{"title":"Aesthetic Consideration in Women's Health, Introduction.","authors":"Lauren Meshkov Bonati,&nbsp;Mona Sadeghpour,&nbsp;Nicola A Quatrano","doi":"10.12788/j.sder.2018.058","DOIUrl":"https://doi.org/10.12788/j.sder.2018.058","url":null,"abstract":"<p><p></p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 4","pages":"209"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36717178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Common allergens present in personal care products: identification, diagnosis, and management. 个人护理产品中常见的过敏原:识别、诊断和管理。
Seminars in cutaneous medicine and surgery Pub Date : 2018-12-01 DOI: 10.12788/j.sder.2018.029
Margaret Chou, Daniela Mikhaylov, Tamara Lazic Strugar
{"title":"Common allergens present in personal care products: identification, diagnosis, and management.","authors":"Margaret Chou,&nbsp;Daniela Mikhaylov,&nbsp;Tamara Lazic Strugar","doi":"10.12788/j.sder.2018.029","DOIUrl":"https://doi.org/10.12788/j.sder.2018.029","url":null,"abstract":"<p><p>The incidence of allergic contact dermatitis (ACD) reactions to personal care products has progressively increased, affecting women more so than men. Fragrances and preservatives are the major sensitizers behind cosmetic-induced ACD, due to their ubiquitous presence in these products, though emulsifiers, ultraviolet filters, and botanical allergens have been implicated as well. While patch testing is the standard for diagnosing ACD, many cosmetic-specific antigens are not currently included within the commercially available kits. Therefore, patch testing for potential cosmetic-induced ACD should be supplemented with additional compounds commonly found in personal use products. Effective treatment of ACD must involve accurate identification and removal of the offending agent.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 4","pages":"254-262"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36764947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The vaginal wellness consultation for treatment with energy-based devices. 使用能量设备进行治疗的阴道健康咨询。
Seminars in cutaneous medicine and surgery Pub Date : 2018-12-01 DOI: 10.12788/j.sder.2018.054
Misha D Miller
{"title":"The vaginal wellness consultation for treatment with energy-based devices.","authors":"Misha D Miller","doi":"10.12788/j.sder.2018.054","DOIUrl":"https://doi.org/10.12788/j.sder.2018.054","url":null,"abstract":"<p><p></p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 4","pages":"233-235"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36717179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
ALIGN PsA: Advancing a Multidisciplinary Approach in PsA. ALIGN PsA:推进PsA的多学科方法。
Seminars in cutaneous medicine and surgery Pub Date : 2018-12-01 DOI: 10.12788/j.sder.2018.057
Eric W Baum, Sergio Schwartzman
{"title":"ALIGN PsA: Advancing a Multidisciplinary Approach in PsA.","authors":"Eric W Baum,&nbsp;Sergio Schwartzman","doi":"10.12788/j.sder.2018.057","DOIUrl":"https://doi.org/10.12788/j.sder.2018.057","url":null,"abstract":"<p><p>Psoriasis is a chronic skin condition that is associated with several comorbidities and co-manifestations that reduce patient quality of life. Psoriatic arthritis (PsA) is a form of spondyloarthritis that is associated with psoriasis and typically involves peripheral disease, axial disease, enthesitis, dactylitis, and skin and nail lesions. Psoriatic arthritis is associated with a substantial psychosocial and functional burden and can lead to irreversible joint damage if left untreated. Early and accurate diagnosis of PsA is critical. The symptoms of PsA span the fields of dermatology and rheumatology, and professional societies recommend co-management between rheumatologists and dermatologists to optimally treat the condition. Dermatologists must be familiar with the hallmarks of PsA, while rheumatologists should understand the impact that cutaneous manifestations of PsA can have on quality of life. Current models of co-management include combined clinics and virtual clinics, which have had success in case reports. Co-management of PsA has been associated with more use of biologics, better preventive care, and higher patient satisfaction.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 6S","pages":"S125-S134"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36821072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Updates on the understanding and treatment of cellulite. 了解和治疗脂肪团的最新进展。
Seminars in cutaneous medicine and surgery Pub Date : 2018-12-01 DOI: 10.12788/j.sder.2018.056
Sara Hogan, Mara Weinstein Velez, Michael S Kaminer
{"title":"Updates on the understanding and treatment of cellulite.","authors":"Sara Hogan,&nbsp;Mara Weinstein Velez,&nbsp;Michael S Kaminer","doi":"10.12788/j.sder.2018.056","DOIUrl":"https://doi.org/10.12788/j.sder.2018.056","url":null,"abstract":"<p><p>Cellulite is a common dermatologic condition and frequent cause of cosmetic concern among women. This paper aims to update what is known about the pathogenesis of cellulite and reviews targeted treatment modalities that address its underlying components of microvascular dysfunction, endocrine-mediated inflammation, and connective tissue fibrosclerosis.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 4","pages":"242-246"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36717177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Using targeted therapies for inflammatory dermatoses. 使用靶向治疗炎症性皮肤病。
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.050
Jeffrey M Sobell
{"title":"Using targeted therapies for inflammatory dermatoses.","authors":"Jeffrey M Sobell","doi":"10.12788/j.sder.2018.050","DOIUrl":"https://doi.org/10.12788/j.sder.2018.050","url":null,"abstract":"","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"133"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36491871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted therapies for psoriatic arthritis: an update for the dermatologist. 银屑病关节炎的靶向治疗:皮肤科医生的最新进展。
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.045
Scott A Elman, Michael Weinblatt, Joseph F Merola
{"title":"Targeted therapies for psoriatic arthritis: an update for the dermatologist.","authors":"Scott A Elman,&nbsp;Michael Weinblatt,&nbsp;Joseph F Merola","doi":"10.12788/j.sder.2018.045","DOIUrl":"https://doi.org/10.12788/j.sder.2018.045","url":null,"abstract":"<p><p>Dermatologists are on the front line to identify psoriatic arthritis (PsA) in their patients with psoriasis. PsA is a prevalent and underdiagnosed disease with potential long-term complications and sequelae for patients. Targeted biologics have transformed the landscape of psoriasis and PsA therapy. These medications variably treat clinical manifestations of psoriatic disease: skin psoriasis, peripheral and axial arthritis, enthesitis, and nail disease. With many new medications either on the market or currently being evaluated by the Food and Drug Administration, the purpose of this article is to review PsA for the dermatologist, to identify the current therapies that are available, and to help select which patients may benefit from these medications. Overall, it is important to decide therapy for patients based on the active domains of their disease, their comorbidities, and the safety profiles of these medications, as well as patient preference for route of administration, frequency, and tolerability.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"173-181"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36491869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
TNF inhibitors for psoriasis. 银屑病的TNF抑制剂。
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.039
Margot Chima, Mark Lebwohl
{"title":"TNF inhibitors for psoriasis.","authors":"Margot Chima,&nbsp;Mark Lebwohl","doi":"10.12788/j.sder.2018.039","DOIUrl":"https://doi.org/10.12788/j.sder.2018.039","url":null,"abstract":"<p><p>Tumor necrosis factor (TNF)-α has been identified as a key cytokine mediating cutaneous inflammation in the pathogenesis of psoriasis. The TNF inhibitors (TNFi's) infliximab, adalimumab, and etanercept are efficacious, Food and Drug Administration-approved medications for the treatment of moderate-to-severe plaque psoriasis. Each drug has a unique pharmacological profile that can have therapeutic implications when choosing a particular TNFi for a patient. An understanding of these idiosyncrasies can help guide therapeutic decisions for patients with psoriasis that also have inflammatory bowel disease, hepatitis C, hepatitis B, latent tuberculosis, obesity, cardiovascular disease, and heart failure. It can also help when selecting the right treatment for pregnant patients, children and adolescents, or those with insurance constraints or compliance issues.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"134-142"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36491872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 28
IL-17 inhibitors for psoriasis. IL-17抑制剂治疗银屑病。
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.051
So Yeon Paek, Jillian Frieder, Dario Kivelevitch, M Alan Menter
{"title":"IL-17 inhibitors for psoriasis.","authors":"So Yeon Paek,&nbsp;Jillian Frieder,&nbsp;Dario Kivelevitch,&nbsp;M Alan Menter","doi":"10.12788/j.sder.2018.051","DOIUrl":"https://doi.org/10.12788/j.sder.2018.051","url":null,"abstract":"<p><p>The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatment of moderate-to-severe plaque psoriasis. Clinical efficacy, safety, and tolerability of each agent is reviewed.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"148-157"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36492426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
IL-23 inhibitors for moderate-to-severe psoriasis. IL-23抑制剂治疗中重度牛皮癣。
Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI: 10.12788/j.sder.2018.047
Erin Ibler, Kenneth B Gordon
{"title":"IL-23 inhibitors for moderate-to-severe psoriasis.","authors":"Erin Ibler,&nbsp;Kenneth B Gordon","doi":"10.12788/j.sder.2018.047","DOIUrl":"https://doi.org/10.12788/j.sder.2018.047","url":null,"abstract":"<p><p>Since the identification of high levels of interleukin 23 (IL- 23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit. At this time, 2 inhibitors of IL-23 p19 have been approved by the United States Food and Drug Administration, guselkumab and tildrakizumab. Two other agents, risankizumab and mirikizumab, have completed phase 3 and phase 2 of development, respectively. Pivotal trials in the development of these agents and clinical use of the approved agents are discussed. Thus far, this class of medications seems to provide a high level of efficacy, along with infrequent dosing and very favorable safety results.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"158-162"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36492425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信